Following Two Years of Promising RNAi Collab, Novo Nordisk Decides to Acquire Dicerna for $3.3 Billion
Almost exactly two years later, Novo Nordisk has decided to completely acquire the Lexington, MA-based biotech in an all-cash deal for $38.25 per share that amounts to a total of $3.3 billion in equity value. This represents a premium of almost 80% to Dicerna's closing price on Wednesday. The M&A deal is expected to close in the fourth quarter of 2021, said the company in a statement. It also expects to initiate clinical development with the first target next year.